3rd Jan 2023
Celix Pharma announces the launch of Bexarotene soft-gel Capsules.
Celix Pharma is pleased to announce the launch of Bexarotene 75mg soft-gel capsules in the UK. Bexarotene 75mg is available in a child-resistant, HDPE bottle pack containing 100 capsules.
Bexarotene is a third-generation retinoid and is indicated for the treatment of advanced skin cancers called cutaneous T-cell lymphomas. Bexarotene works by slowing or stopping the growth of cancer cells (1,2,3).
Commenting on this launch, Subir Kohli, Co-founder & CEO said, “We are excited to launch another product for the specialist hospital channel. Bexarotene is a niche, high-cost drug in the derma-oncology space and launching the first generic equivalent in the UK, with substantial savings to the NHS reaffirms our values of bringing high-quality, affordable, life-saving medicines into the UK.”
Shantreddy, Co-founder & COO added, “As a suspension in soft-gel capsule, Bexarotene presents unique development and manufacturing challenges which we are glad to have overcome alongside our partner.”
About Celix Pharma Ltd
Celix Pharma is a London-based generic pharmaceutical company founded in 2020 with an overarching goal to bring high quality, affordable, generic medicines with a sustainable supply chain to the UK. Celix Pharma focuses on bridging gaps in the market by identifying product opportunities arising from complexities in development and/or manufacturing, addressing supply disruptions and future patent expiries with a portfolio spanning generics, value-added generics, and hospital specialty products. Celix Pharma’s business model is built around creating a commercially led, customer-focused organization supported with strategic partnerships in R&D and manufacturing.
For more information, visit www.celixpharma.com